Gentian Diagnostics ASA

Regulatory Filings • Jan 22, 2021

SARS-CoV-2 antibody test moving to the next development phase

SARS-CoV-2 antibody test moving to the next development phase

Moss, 22.01.2021

Gentian Diagnostics AS is pleased to announce that its high-throughput SARS-CoV-2 antibody test project has moved from the proof-of-concept phase to the project initiation and optimisation phase. An official project plan has been established with an approved budget and a dedicated project team, moving the project forward. The timeline to launch is set to Q4 2021.

The aim for the SARS-CoV-2 antibody test is to offer the first assay on high-throughput open-access clinical chemistry platforms, that supports vaccination efforts and aid in community management by the determination of immunisation status.

The project is supported by the collaboration with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway, providing expertise and guidance regarding SARS-CoV-2 research and vaccination trends.

Gentian’s CEO Dr. Hilja Ibert commented: “This is truly an outstanding achievement. Our R&D team has managed to bring this marker into the optimisation phase in record time and with the participation from our collaborating partners we will move forward with the assay development."

For further information contact:

Hilja Ibert CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone: +47 919 06 525